Duop.Kl
DUOP.KL operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of pharmaceutical products.
Business. DUOP.KL operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of pharmaceutical products.
Analyst recommendations
6 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DUOP.KL operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of pharmaceutical products.
The company maintains a debt-to-equity ratio of 0.65, indicating a moderate reliance on debt financing, and a current ratio of 2.6, suggesting strong short-term liquidity. However, the risk assessment highlights a medium liquidity risk, with net cash being negative after subtracting total debt, signaling potential pressure on cash reserves.
Profitability metrics show a return on equity (ROE) of 11.54% and a return on assets (ROA) of 6.03%, both of which are above the typical thresholds for the pharmaceutical industry, indicating strong returns relative to equity and asset base. The operating margin, calculated as operating income of MYR 133.79 million on revenue of MYR 931.69 million, is 14.36%, which is a robust margin for the sector.
The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess geographic or segment concentration. However, the lack of disclosed segments suggests a relatively undiversified business model, which could pose a risk if demand for its products declines in a specific market.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline indicated in the outlook. The capital expenditure of MYR -33.18 million suggests a reduction in investment in physical assets, which may reflect a focus on cost control or a shift toward digital or operational efficiency. The free cash flow of MYR 66.13 million indicates the company is generating sufficient cash to support operations and potentially fund dividends or share repurchases.
The risk assessment identifies a low dilution risk, with no significant dilution sources disclosed in the available data. The company's liquidity risk is rated as medium, primarily due to the negative net cash position after accounting for total debt. No major regulatory or geopolitical risks are highlighted in the available data, though the pharmaceutical industry is generally subject to regulatory scrutiny and policy changes.
Recent events, including analyst estimates, suggest a generally positive outlook from the investment community. The mean price target of MYR 1.73 and the median of MYR 1.72 indicate a consensus for a modest increase in share price. The mean recommendation of 1.83, with six "buy" ratings and one "strong buy," reflects a favorable sentiment among analysts.
- The company maintains a strong current ratio of 2.6, indicating solid short-term liquidity.
- Return on equity of 11.54% and return on assets of 6.03% suggest strong profitability relative to its equity and asset base.
- Free cash flow of MYR 66.13 million indicates the company is generating sufficient cash to support operations and potentially fund dividends or share repurchases.
- Analysts have a generally positive outlook, with a mean price target of MYR 1.73 and six "buy" ratings.
- The company has a low dilution risk and a medium liquidity risk, with no significant dilution sources disclosed.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,11 |
| Revenue | —no estimate | —no estimate | 995,7M MYR |
| Operating income | —no estimate | —no estimate | 124,9M MYR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- DUOP.KL Market data — financials · 2026-05-27
- Duopharma Biotech Bhd Market data — analyst estimates · 2026-05-27